For the second time this year, German drugmaker Bayer has nabbed an oncology leader from GlaxoSmithKline, appointing Tara Frenkl, M.D., to lead oncology development for its oncology strategic business unit.
Frenkl will step into her new role April 25 reporting directly to Christine Roth, a previous GSK transfer, now head of Bayer’s oncology strategic business unit for the pharmaceuticals division. Roth left her position leading GSK’s global oncology therapy area earlier this year, joining Bayer on March 1. She replaced Robert LaCaze, who left Bayer for an undisclosed destination.
Frenkl, the newest GSK recruit, had served as the company’s senior vice president and head of medicine development leaders in oncology. Before that, she worked across various roles at Merck for more than 13 years.
Known as a major player in the cardiovascular disease space, Bayer appears to be beefing up its foothold in oncology. GSK has been doing the same thing since 2019, when the company reestablished itself in the commercial cancer market with the acquisition of Tesaro, maker of PARP inhibitor Zejula.
Roth and Frenkl will likely focus efforts on Bayer’s prostate cancer med Nubeqa, for which the company has high hopes. The drug, approved in 2019 for men with non-metastatic castration-resistant prostate cancer, has experienced a slow launch thus far. The androgen receptor inhibitor has yet to make Bayer’s list of top 20 drugs, based on third quarter financial results.
Stiff competition from strong rivals such as Pfizer and Astellas’ Xtandi and J&J’s Erleada, in tandem with the ongoing pandemic, may point to why Nubeqa’s ramp up has been slow-moving. However, the drug could potentially expand its label soon into metastatic hormone-sensitive prostate cancer.
Bayer also sells the radiotherapy medicine Xofigo for prostate cancer and recently acquired Noria Therapeutics and subsidiary PSMA Therapeutics, gaining control of two investigational radiotherapies in prostate cancer.
By Gabrielle Masson
Source: fiercebiotech.com
CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.
DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.
Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.
